208 related articles for article (PubMed ID: 24744444)
1. The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging—first preclinical studies.
Gourni E; Waser B; Clerc P; Fourmy D; Reubi JC; Maecke HR
J Nucl Med; 2014 Jun; 55(6):976-82. PubMed ID: 24744444
[TBL] [Abstract][Full Text] [Related]
2. Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.
Rylova SN; Waser B; Del Pozzo L; Tönnesmann R; Mansi R; Meyer PT; Reubi JC; Maecke HR
J Nucl Med; 2016 Aug; 57(8):1282-8. PubMed ID: 27127218
[TBL] [Abstract][Full Text] [Related]
3. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
[TBL] [Abstract][Full Text] [Related]
4. Characterization of
Willekens SMA; Joosten L; Boerman OC; Brom M; Gotthardt M
Sci Rep; 2018 Feb; 8(1):2948. PubMed ID: 29440684
[TBL] [Abstract][Full Text] [Related]
5. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.
Waser B; Rehmann R; Sanchez C; Fourmy D; Reubi JC
J Clin Endocrinol Metab; 2012 Feb; 97(2):482-8. PubMed ID: 22112810
[TBL] [Abstract][Full Text] [Related]
6. Introduction of a fatty acid chain modification to prolong circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor.
Khalil A; Hakhverdyan S; Cheung P; Bossart M; Wagner M; Eriksson O; Velikyan I
Nucl Med Biol; 2024; 128-129():108876. PubMed ID: 38241936
[TBL] [Abstract][Full Text] [Related]
7. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
[TBL] [Abstract][Full Text] [Related]
8. Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs.
Reubi JC; Waser B
J Nucl Med; 2015 Apr; 56(4):613-5. PubMed ID: 25698785
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
[TBL] [Abstract][Full Text] [Related]
10. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET.
Bauman A; Valverde IE; Fischer CA; Vomstein S; Mindt TL
J Nucl Med; 2015 Oct; 56(10):1569-74. PubMed ID: 26251418
[TBL] [Abstract][Full Text] [Related]
11. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
13. Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography.
Eriksson O; Velikyan I; Haack T; Bossart M; Evers A; Lorenz K; Laitinen I; Larsen PJ; Plettenburg O; Johansson L; Pierrou S; Wagner M
Diabetes; 2021 Apr; 70(4):842-853. PubMed ID: 33547046
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
15. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
16.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
17. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
18. Safety, Biodistribution, and Radiation Dosimetry of
Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
[TBL] [Abstract][Full Text] [Related]
19. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
20. Human GIP(3-30)NH
Gabe MBN; Sparre-Ulrich AH; Pedersen MF; Gasbjerg LS; Inoue A; Bräuner-Osborne H; Hartmann B; Rosenkilde MM
Biochem Pharmacol; 2018 Apr; 150():97-107. PubMed ID: 29378179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
